GlassScriptPhysician profile
Edward M Harding
NPI 1871556415
$631.50
in general payments reported to CMS, 2019-2025
17 companies · $64.06 in 2025
The $64.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $97.42 · 2021: $68.65 · 2022: $15.21 · 2023: $83.34 · 2024: $79.90 · 2025: $64.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.35 | 2019-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.23 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $48.39 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $44.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.86 | 2019-2020 | |
| Novo Nordisk INC | $35.92 | 2019-2020 | |
| Pfizer INC. | $30.32 | 2020-2022 | |
| Dexcom, INC. | $28.69 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $23.35 | 2023 | Otezla, Repatha |
| Horizon Therapeutics Plc | $22.47 | 2023 | Krystexxa |
| Lucid Diagnostics INC. | $20.41 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.90 | 2019 | |
| Glaxosmithkline, LLC. | $16.88 | 2019 | |
| Astellas Pharma US INC | $16.41 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $15.97 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.71 | 2024 | Jardiance |
| Genentech USA, INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.